Market Overview:
The global anti-nuclear antibody (ANA) testing market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The market growth is attributed to the increasing prevalence of autoimmune diseases, technological advancements in the field of diagnostics, and rising demand for early diagnosis and treatment. The global anti-nuclear antibody (ANA) testing market is segmented by type, application, and region. By type, the market is divided into indirect immunofluorescence assay (IFA), enzyme-linked immunosorbent assay (ELISA), other tests such as radioimmunoassay (RIA) and chemiluminescence immunoassay (CLIA), and western blotting. ELISA held the largest share of the global ANA testing market in 2017 owing to its high accuracy and reliability. By application, hospital held the largest share of the global ANA testing market in 2017 owing to increased awareness about autoimmune diseases among patients and healthcare professionals coupled with rising demand for early diagnosis and treatment options.
Product Definition:
ANA testing is a blood test that checks for antibodies against the proteins in the nucleus of cells. This type of antibody is called an anti-nuclear antibody (ANA). ANA testing is used to help diagnose autoimmune diseases and other conditions.
Indirect Immunofluorescence:
The indirect immunofluorescence (IF) is a method used for the detection ofANA in patients with chronic diseases such as rheumatoid arthritis. The test uses antibodies that are directed against the body's own nucleic acids to identify and label cells that containRNA or DNA, which then allows them to be identified and measured by fluorescence microscopy.
Enzyme-linked Immunosorbent Assay (ELISA):
An enzyme-linked immunosorbent assay (ELISA) is a procedure to detect the presence of an antibody in the human blood. It is one of the most common procedures used for testing ANA. The ELISA test can be performed on fresh or frozen samples and it does not require special storage conditions.
Global Enzyme-linked Immunosorbent Assay (ELISA).
Application Insights:
The other application segment held the largest share of over 70.0% in 2017. The growing awareness about the use of nuclear medicine for imaging and testing is one of the key factors driving this segment growth. Nuclear Medicine Technologist (NMT) is an essential position in hospitals, clinics, and other healthcare facilities that perform daily nuclear medicine procedures to ensure accurate results are obtained by patients undergoing diagnostic procedures involving radioisotopes or radionuclei therapy.
In addition, a rise in demand for low cost effective solutions to diagnose chronic diseases such as cancer is expected to boost product adoption across various applications during the forecast period.
Regional Analysis:
North America dominated the global anti-nuclear antibody testing market in 2017. The presence of a large number of nuclear power plants and manufacturing facilities coupled with high healthcare expenditure levels, favorable reimbursement policies, and increasing awareness levels are some factors driving the regional market growth.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to growing concerns regarding radiation exposure due to nuclear accidents as well as increased demand for electricity supply from developing countries such as China and India. In addition, rising incidence of cancer in Japan has led it to establish a working group that includes researchers from across Asia Pacific aimed at exploring new avenues for cancer treatment using antibodies against radioactive substances. This factor is also anticipated to drive revenue generation in this region during the forecast period.
Growth Factors:
- Increasing incidence of autoimmune diseases: The global prevalence of autoimmune diseases is increasing at an alarming rate. This is primarily attributed to the changing lifestyles and environmental factors. The ANA test helps in early diagnosis and treatment of these diseases, thereby aiding in their management.
- Growing awareness about autoimmune disorders: There is a growing awareness among people about the various types of autoimmune disorders and their symptoms. This has led to an increase in the demand for ANA testing services worldwide.
- Technological advancements in immunoassay techniques: Immunoassay techniques are constantly evolving, with new technologies being developed every day to make them more sensitive and specific for detecting autoantibodies present in blood samples. This is resulting in an increase in the adoption of ANA tests by diagnostic laboratories worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Anti-nuclear Antibody (ANA) Testing Market Research Report
By Type
Indirect Immunofluorescence, Enzyme-linked Immunosorbent Assay (ELISA), Other,
By Application
Hospital, Clinic, Other,
By Companies
Abcam, Antibodies, Bio-Rad Laboratories, Alere, Erba Diagnostics, MBL International, Merck, Indur Services, Trinity Biotech, Thermo Fisher Scientific, Zeus Scientific,
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Anti-nuclear Antibody (ANA) Testing Market Report Segments:
The global Anti-nuclear Antibody (ANA) Testing market is segmented on the basis of:
Types
Indirect Immunofluorescence, Enzyme-linked Immunosorbent Assay (ELISA), Other,
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abcam
- Antibodies
- Bio-Rad Laboratories
- Alere
- Erba Diagnostics
- MBL International
- Merck
- Indur Services
- Trinity Biotech
- Thermo Fisher Scientific
- Zeus Scientific
Highlights of The Anti-nuclear Antibody (ANA) Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Indirect Immunofluorescence
- Enzyme-linked Immunosorbent Assay (ELISA)
- Other
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-nuclear Antibody (ANA) Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
ANA testing is a blood test that checks for the presence of antibodies against nuclear substances. This includes tests for radioactive materials, such as uranium and plutonium. ANA testing can help identify people who have been exposed to radiation, or who may be at risk of developing cancer from radiation exposure.
Some of the major players in the anti-nuclear antibody (ana) testing market are Abcam, Antibodies, Bio-Rad Laboratories, Alere, Erba Diagnostics, MBL International, Merck, Indur Services, Trinity Biotech, Thermo Fisher Scientific, Zeus Scientific.
The anti-nuclear antibody (ana) testing market is expected to register a CAGR of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anti-nuclear Antibody (ANA) Testing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Anti-nuclear Antibody (ANA) Testing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Anti-nuclear Antibody (ANA) Testing Market - Supply Chain
4.5. Global Anti-nuclear Antibody (ANA) Testing Market Forecast
4.5.1. Anti-nuclear Antibody (ANA) Testing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Anti-nuclear Antibody (ANA) Testing Market Size (000 Units) and Y-o-Y Growth
4.5.3. Anti-nuclear Antibody (ANA) Testing Market Absolute $ Opportunity
5. Global Anti-nuclear Antibody (ANA) Testing Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Type
5.3.1. Indirect Immunofluorescence
5.3.2. Enzyme-linked Immunosorbent Assay (ELISA)
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Anti-nuclear Antibody (ANA) Testing Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Anti-nuclear Antibody (ANA) Testing Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Anti-nuclear Antibody (ANA) Testing Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Anti-nuclear Antibody (ANA) Testing Demand Share Forecast, 2019-2026
9. North America Anti-nuclear Antibody (ANA) Testing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Type
9.7.1. Indirect Immunofluorescence
9.7.2. Enzyme-linked Immunosorbent Assay (ELISA)
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Anti-nuclear Antibody (ANA) Testing Demand Share Forecast, 2019-2026
10. Latin America Anti-nuclear Antibody (ANA) Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Type
10.7.1. Indirect Immunofluorescence
10.7.2. Enzyme-linked Immunosorbent Assay (ELISA)
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Anti-nuclear Antibody (ANA) Testing Demand Share Forecast, 2019-2026
11. Europe Anti-nuclear Antibody (ANA) Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Type
11.7.1. Indirect Immunofluorescence
11.7.2. Enzyme-linked Immunosorbent Assay (ELISA)
11.7.3. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Anti-nuclear Antibody (ANA) Testing Demand Share, 2019-2026
12. Asia Pacific Anti-nuclear Antibody (ANA) Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Type
12.7.1. Indirect Immunofluorescence
12.7.2. Enzyme-linked Immunosorbent Assay (ELISA)
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Anti-nuclear Antibody (ANA) Testing Demand Share, 2019-2026
13. Middle East & Africa Anti-nuclear Antibody (ANA) Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Anti-nuclear Antibody (ANA) Testing Market Size and Volume Forecast by Type
13.7.1. Indirect Immunofluorescence
13.7.2. Enzyme-linked Immunosorbent Assay (ELISA)
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Anti-nuclear Antibody (ANA) Testing Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Anti-nuclear Antibody (ANA) Testing Market: Market Share Analysis
14.2. Anti-nuclear Antibody (ANA) Testing Distributors and Customers
14.3. Anti-nuclear Antibody (ANA) Testing Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abcam
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Antibodies
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bio-Rad Laboratories
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Alere
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Erba Diagnostics
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. MBL International
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Merck
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Indur Services
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Trinity Biotech
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Thermo Fisher Scientific
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Zeus Scientific
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12.
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook